Crispr Therapeutics AG (NASDAQ:CRSP) Director Kurt Von Emster sold 37,754 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $26.76, for a total value of $1,010,297.04. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.39 during trading on Thursday, reaching $23.91. The company had a trading volume of 706,365 shares, compared to its average volume of 998,167. The firm has a market capitalization of $987.75 and a price-to-earnings ratio of -74.72. Crispr Therapeutics AG has a 52-week low of $11.63 and a 52-week high of $27.39.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million for the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business’s revenue was up 54.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.77) earnings per share. research analysts forecast that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.
CRSP has been the topic of several recent research reports. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Piper Jaffray Companies initiated coverage on Crispr Therapeutics in a research report on Friday, December 22nd. They issued an “overweight” rating on the stock. SunTrust Banks restated a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research report on Friday, November 10th. Finally, Barclays restated a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a research report on Friday, September 8th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $22.38.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.